NASDAQ:MNKDMannKind Stock Price, Forecast & News

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 30.9% and is now trading at $1.44. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MannKind.

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MannKind.

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The biopharmaceutical company had revenue of $16.24 million for the quarter, compared to analyst estimates of $15.15 million. View MannKind's earnings history.

4 equities research analysts have issued 12 month price targets for MannKind's shares. Their forecasts range from $2.50 to $3.00. On average, they anticipate MannKind's share price to reach $2.67 in the next year. This suggests a possible upside of 85.2% from the stock's current price. View analysts' price targets for MannKind.

Media coverage about MNKD stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MannKind earned a news impact score of -3.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutMannKind.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHK), Gilead Sciences (GILD), Micron Technology (MU), Geron (GERN), NVIDIA (NVDA) and Intel (INTC).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.98%), State Street Corp (1.60%), Geode Capital Management LLC (1.26%), Nuveen Asset Management LLC (0.43%), Dupont Capital Management Corp (0.31%) and Bank of New York Mellon Corp (0.26%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View institutional ownership trends for MannKind.

MNKD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Parametric Portfolio Associates LLC, Deutsche Bank AG, BlackRock Inc., Raymond James & Associates, Wells Fargo & Company MN, State Street Corp, and Legal & General Group Plc. View insider buying and selling activity for MannKind.

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Geode Capital Management LLC, Advisor Group Holdings Inc., Alliancebernstein L.P., Dupont Capital Management Corp, SG Americas Securities LLC, 180 Wealth Advisors LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross. View insider buying and selling activity for MannKind.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MNKD stock can currently be purchased for approximately $1.44.

MannKind has a market capitalization of $306.92 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe.

The official website for MannKind is www.mannkindcorp.com.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]